< Terug naar vorige pagina
Publicatie
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial
Tijdschriftbijdrage - Tijdschriftartikel
Tijdschrift: BMC CANCER
ISSN: 1471-2407
Issue: 1
Volume: 20
Jaar van publicatie:2020
Toegankelijkheid:Open
- Zie ook: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
- Zie ook: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial